⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775806 | 1.00 | — | — | |
| SCHEMBL2205953 | 1.00 | — | — | |
| SCHEMBL19128284 | 0.83 | — | — | |
| SCHEMBL9833318 | 0.83 | — | — | |
| SCHEMBL15879468 | 0.79 | HLCS (0.32) | — | |
| SCHEMBL15879470 | 0.79 | HLCS (0.32) | — | |
| SCHEMBL14638692 | 0.79 | — | — | |
| SCHEMBL17365148 | 0.78 | — | — | |
| SCHEMBL23535429 | 0.77 | — | — | |
| SCHEMBL18360767 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-02-22 | — | — | US | disclosed |
| EP-2970240-B1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9688672-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-6372778-B1 | AMINE HYDROXYALKYL SULFONAMIDE AS ENZYME INHIBITORS | VERTEX PHARMACEUTICALS, INCORPORATED | 2002-04-16 | — | — | US | disclosed |
| US-6004957-A | VIRICIDES FOR HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-12-21 | — | — | US | disclosed |
| US-5977137-A | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0659181-B1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMA (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5856353-A | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0885887-A2 | Sulfonamide inhibitors of HIV-Aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5783701-A | ANTI-HIV VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-07-21 | — | — | US | disclosed |
| US-5585397-A | VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0659181-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005639-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-17 | — | — | WO | disclosed |